Industry-wide, only 67.9% of display ad impressions served globally are actually viewable, meaning roughly a third of what gets counted and billed as an "impression" was never placed where a human being could see it (IAS Media Quality Report, 2026). That's the industry average across every category, not a pharma-specific number, and it's already a large gap. For pharma brands, there's a second gap layered on top of it: even a genuinely viewable impression doesn't confirm that the person who saw it was actually the HCP or patient the campaign was built for.
Most digital advertising measurement stops at the first layer. A campaign dashboard reports impressions served, clicks, and maybe a viewability rate pulled from the ad server. None of that confirms who was actually reached, or whether seeing the ad changed anything about how that person thinks about the brand.
It helps to separate three distinct layers that get collapsed into a single "impressions" number more often than they should be.
A served impression simply means an ad request was fulfilled and content was returned to a page or app. It says nothing about whether the ad ever rendered somewhere a person could see it.
A viewable impression meets a minimum visibility standard, typically at least 50% of the ad's pixels on screen for one second for display, or two seconds for video, per the Media Rating Council standard most platforms report against. This is the number the 67.9% figure above refers to, and it's already a meaningful filter on what "served" really means.
A verified exposure goes further still: it confirms that a specific, identified member of the target audience, not a generic browser or device, actually encountered the content. This is the layer standard ad platforms generally can't provide, because they're built to report on delivery and clicks, not on confirmed audience identity.
Served versus viewable. Even setting pharma aside, close to a third of display impressions industry-wide never meet basic viewability standards. A campaign report built purely on served impressions is already overstating real reach before any pharma-specific issue enters the picture.
Viewable versus verified audience. A viewable impression confirms an ad rendered on screen. It doesn't confirm the screen belonged to an oncologist, a rheumatology nurse practitioner, or a patient actively researching a condition, rather than an unrelated visitor to the same publisher. Standard ad platforms verify placement, not identity, which means a brand can have a strong viewability rate and still not know whether it reached the audience the campaign was built for.
Clicks versus brand impact. Click-through rate and conversion metrics describe what happened on the page. They say nothing about whether the ad shifted awareness, consideration, or prescribing intent, the outcomes brand teams actually care about. A campaign can perform well on every platform-reported metric and still not move the metrics that matter to a brand plan.
Closing these gaps requires a different measurement approach: observing exposure directly from a confirmed panel of target HCPs and patients, rather than inferring it from platform-reported delivery data. Digital Tracker is built on this model. It passively captures over 410,000 banner ad impressions and 44,000-plus paid search impressions every month from verified panelists who are confirmed members of the target audience, not a modeled sample or a generic device ID. That closes both of the first two gaps at once: the impressions being counted are confirmed viewable exposures, and the audience behind them is confirmed to be the right one.
Verified exposure solves the "who actually saw it" problem. It doesn't automatically answer whether seeing the ad changed anything. That requires pairing exposure data with a separate read on brand perception, which is where an impact or brand lift survey comes in: measuring awareness, consideration, and prescribing intent among the same verified audience, then connecting shifts in those metrics back to which channels that audience was actually exposed to.
That pairing turns a measurement report into something closer to a decision tool. Instead of "channel X had a 0.4% click-through rate," a brand team can see "physicians exposed to channel X showed a measurable lift in treatment consideration, while channel Y showed none," which is a very different basis for reallocating a media budget than click-through rate alone.
Once measurement is built on verified exposure rather than modeled or platform-reported impressions, a few things become possible that weren't before. Brand teams can compare channels on a like-for-like basis, since every number reflects the same standard of confirmed audience exposure rather than a mix of served impressions on some channels and viewable impressions on others. That same standard makes share of voice comparisons against competitors more trustworthy too, since both sides of the calculation are built from confirmed exposure rather than a modeled estimate. Mid-flight budget shifts can be made with more confidence, because underperformance shows up as a real gap in verified reach or brand impact rather than a platform-reported metric that may not reflect actual audience exposure at all. And post-campaign reporting holds up better to scrutiny, since the underlying data was observed directly rather than modeled or self-reported by the platforms selling the media.
Want to see verified exposure data for your own channel mix? Reach out to the Digital Tracker team.